Date of board meeting
Filed with HKEX · Stock code 1093 · · 1 page · English
Summary by 6ix AI
CSPC Pharmaceutical Group Limited has announced the date of its upcoming board meeting. The meeting is scheduled for a specific date to approve the unaudited consolidated results for a recent nine-month period. The announcement includes details about the board members and their roles.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
CSPC Pharmaceutical Group Limited on 6ix
Earlier from CSPC Pharmaceutical
- Voluntary announcement - Phase I/II clinical trial of SYS6062 for the treatment of advanced solid tumours officially initiated at the first centre in China
- Voluntary announcement - phase II clinical trial of SYH2072 tablets for the treatment of uncontrolled hypertension and resistant hypertension officially initiated at the first centre in China
- Monthly return of equity issuer on movements in securities for the month ended 31 October 2026
- Voluntary announcement - phase III clinical trial of prusogliptin tablets in combination with dapagliflozin tablets and metformin hydrochloride extended-release tablets for the treatment of type 2 diabetes mellitus achieves positive topline results
- Voluntary announcement - Phase I/II clinical trial of SYS6052 (recombinant herpes zoster virus vaccine (cho cells)) officially initiated in China
Later from CSPC Pharmaceutical
- Voluntary announcement - Phase I/II clinical trial of SYS6055 injection for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma officially initiated at the first centre in China
- Voluntary announcement - Phase II clinical trial of SYH9061 for the treatment of idiopathic pulmonary fibrosis officially initiated at the first centre in China
Follow CSPC Pharmaceutical into a list and get an email when it puts out news.
Follow CSPC Pharmaceutical